Recently, the immune check point inhibitors, especially anti-PD-1 (programmed cell death protein 1) drugs, had shown great benefits to cancer patients.[9] The predictive biomarkers for PD-1 inhibitors involved the increased expression of the programmed death ligand 1 (PD-L1) proteins and CD8[+] lymphocyte infiltrations.[10,11] Herein, we reported a case of the plurihormonal pituitary adenoma, in which the tumors were detected PD-L1 proteins and CD8+ lymphocyte infiltrations. Here, PDCD1 is linked to cancer.